摘要
目的 分析拉米夫定联合阿德福韦酯与恩替卡韦在治疗慢性乙型肝炎患者疗效的差异,为慢性乙型肝炎初治患者提供恰当的治疗方案.方法 根据用药方法不同,将120例慢性乙型肝炎患者分为拉米夫定联合阿德福韦酯组（联合治疗组）和恩替卡韦组,每组60例.记录不同治疗时间点两组ALT复常、HBeAg转阴和HBV DNA低于检测值的患者例数,并进行组间比较.结果 联合治疗组和恩替卡韦组在治疗第3、6、12个月时ALT复常两组差异均无统计学意义（x2=2.194、2.353、3.339,P＞0.05）;治疗第3、6、12、18个月时,HBeAg阴转例数两组差异均无统计学意义（x2=0.054、0.139、0.326、0.152,P＞0.05）;治疗第6、12、18、24个月时,两组HBV DNA低于检测值的例数差异均无统计学意义（x2=0.348、0.348、2.236、0.776,P＞0.05）.结论 拉米夫定联合阿德福韦酯与恩替卡韦治疗慢性乙型肝炎在肝酶水平、HBV血清学和病毒学转变方面的疗效差异无统计学意义.
Objective To analyze the effect of lamivudine combined with adefovir and entecavir in treatment of chronic hepatitis B patients, to provide the basis for felicitous treatment. Methods 120 cases of chronic hepatitis B patients were divided into two groups（lamivudine combined with adefovir group and entecavir group） according to the method of treatment. The clinical data of two groups were recorded, including the cases of ALT normalization, HBeAg negative conversion and HBV DNA below to the detection level in different treatment time. Results After 3, 6, 12 months of treatment, there was no statistical difference between the two groups in ALT normalization （ x2 = 2.194,2.353,3.339, P〉 0.05）; and there was no statistical difference in the incidence of HBeAg negative after 3,6,12.18 months of treatment too（x2 = 0.054,0.139,0.326,0.152, P 〉 0.05）. There was no statistical difference in the incidence of HBV DNA returned to nagative after 6,12, 18,24 months trentment （ x2 = 0.348,0.348,2.236,0.776, P 〉 0.05）. Conclusions There was no difference in the ALT normalization, the incidence of HBeAg negative conversion and the incidence of HBV DNA retumed to nagative in lamivudine combined with adefovir and entecavir for chronic hepatitis B.
出处
《国际流行病学传染病学杂志》
CAS
2010年第5期309-311,共3页
International Journal of Epidemiology and Infectious Disease
